Research Peptide Blog Database
Peer-reviewed studies, clinical data, mechanism breakdowns, and molecular specifications — all in one place.
Modified GRF(1-29) · GHRH Receptor Agonist
CJC-1295 (No DAC)
GHRH analog. For in vitro research use only.
Published Scientific Research
Peer-reviewed studies investigating CJC-1295 (No DAC) sourced from PubMed-indexed journals for educational reference only.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.
View Full Study on PubMed →Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
Although the majority of children with isolated growth hormone (GH) deficiency have a good growth response to GH-releasing hormone (GHRH), the use of this therapeutic agent is limited by its very short half-life. Indeed, we...
View Full Study on PubMed →Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Pulsatile GH secretion is considered important for many of the hormone's physiological effects. Short-term GHRH infusions enhance GH pulsatility and increase IGF-I, but the short GHRH half-life limits its therapeutic use. A synthetic GHRH analog...
View Full Study on PubMed →Advances in the detection of growth hormone releasing hormone synthetic analogs.
The administration of growth hormone releasing hormone (GHRH) and its synthetic analogs is prohibited by the World Anti-Doping Agency (WADA). Although there is evidence of their use, based on admissions and intelligence, they do not...
View Full Study on PubMed →An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
CJC-1295 is a 30 amino acid peptide-based drug that stimulates the release of growth hormone (GH) from the pituitary gland. It is unique among performance-enhancing peptides due to the presence of a reactive maleimidopropionic acid...
View Full Study on PubMed →Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
To identify biomarkers of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) action in human serum.
View Full Study on PubMed →Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.
For most peptide hormones prohibited in elite sports the concentrations in plasma or urine are very low (pg/mL). Accordingly, hyphenated purification and enrichment steps prior to mass spectrometric detection are required to obtain sufficient doping...
View Full Study on PubMed →Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Growth hormone-releasing hormone (GHRH) and its synthetic analogs are considered performance-enhancing substances and are therefore prohibited by the World Anti-Doping Agency (WADA). The analysis of GHRH and its analogs in urine presents significant analytical challenges...
View Full Study on PubMed →Technical Specifications
🔬 Molecular Profile
🧊 Storage Requirements
Research-Grade CJC-1295 (No DAC)
≥98% purity, third-party COA verified, lyophilized for stability. For in vitro laboratory research use only.
⚠️ Important Research Notice
All compounds listed are intended exclusively for in vitro laboratory research by qualified professionals. Not for human or animal consumption. Not approved by the FDA for any diagnostic, therapeutic, or clinical purpose. All research findings are sourced from peer-reviewed journals for educational reference only. Not to be interpreted as medical advice or product claims.